Drug Profile
Clazakizumab - CSL Behring/Vitaeris
Alternative Names: ALD 518; BMS-645429; BMS-945429; CSL-300Latest Information Update: 27 Jul 2023
Price :
$50
*
At a glance
- Originator Alder Biopharmaceuticals
- Developer CSL Behring; ICON; Lundbeck Seattle BioPharmaceuticals Inc.; Vitaeris
- Class Anti-inflammatories; Antianaemics; Antipsoriatics; Antirheumatics; Antivirals; Monoclonal antibodies
- Mechanism of Action Interleukin 6 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Renal transplant rejection
- Phase II/III Renal failure
- Phase II COVID 2019 infections; Inflammation
- Suspended Anaemia; Cachexia; Fatigue; Stomatitis
- Discontinued Crohn's disease; Graft-versus-host disease; Psoriatic arthritis; Rheumatoid arthritis
Most Recent Events
- 18 Jul 2023 Phase-II clinical trials in Inflammation (In the elderly) in USA (SC) (NCT05727384)
- 29 Nov 2022 Phase-II development in COVID-2019 infections is ongoing in USA (IV) (NCT04343989)
- 29 Nov 2022 Phase III development in Renal transplant rejection is ongoing in USA, Spain and Hungary (SC) (NCT03744910) (EudraCT 2018-003682-34)